TRIAMCINOLONE ACETONIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triamcinolone Acetonide, and what generic alternatives are available?
Triamcinolone Acetonide is a drug marketed by Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Mylan, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Taro, Topiderm, Amneal, Eugia Pharma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Sandoz, Teva Pharms Usa, Watson Labs, Epic Pharma Llc, Pai Holdings Pharm, Quagen, Wockhardt Bio Ag, Aurobindo Pharma Ltd, Cintex Svcs, Glenmark Pharms, Padagis Israel, Akorn, Lyne, Apotex, Perrigo Pharma Intl, Rising, and Saptalis Pharms. and is included in ninety-three NDAs.
The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Triamcinolone Acetonide
A generic version of TRIAMCINOLONE ACETONIDE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for TRIAMCINOLONE ACETONIDE
| US Patents: | 0 |
| Applicants: | 41 |
| NDAs: | 93 |
| Finished Product Suppliers / Packagers: | 57 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 255 |
| Patent Applications: | 4,333 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRIAMCINOLONE ACETONIDE |
| Drug Sales Revenues: | Drug sales revenues for TRIAMCINOLONE ACETONIDE |
| What excipients (inactive ingredients) are in TRIAMCINOLONE ACETONIDE? | TRIAMCINOLONE ACETONIDE excipients list |
| DailyMed Link: | TRIAMCINOLONE ACETONIDE at DailyMed |
See drug prices for TRIAMCINOLONE ACETONIDE
Recent Clinical Trials for TRIAMCINOLONE ACETONIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gadjah Mada University | Phase 1/Phase 2 |
| Innovaderm Research Inc. | Phase 4 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Phase 4 |
Pharmacology for TRIAMCINOLONE ACETONIDE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE ACETONIDE
Anatomical Therapeutic Chemical (ATC) Classes for TRIAMCINOLONE ACETONIDE
US Patents and Regulatory Information for TRIAMCINOLONE ACETONIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | OINTMENT;TOPICAL | 211315-001 | Mar 18, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Pharmaderm | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | OINTMENT;TOPICAL | 088692-001 | Aug 2, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Taro | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 040039-001 | Nov 26, 1997 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Pharmaderm | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 087992-001 | Jul 7, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glenmark Pharms Ltd | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | OINTMENT;TOPICAL | 206379-001 | Jul 22, 2016 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Apotex | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | SPRAY, METERED;NASAL | 214615-001 | Jan 19, 2023 | OTC | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
